Nisa Investment Advisors
ENTA icon

Nisa Investment Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Nisa Investment Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.29K Hold
340
– – ﹤0.01% 2484
2025
Q4 		$5.36K Sell
340
-510
-60% -$6.48K ﹤0.01% 2441
2025
Q3 		$10.2K Hold
850
– – ﹤0.01% 2274
2025
Q2 		$6.43K Sell
850
-808
-49% -$4.86K ﹤0.01% 2403
2025
Q1 		$9.15K Buy
1,658
+1,123
+210% +$6.94K ﹤0.01% 2120
2024
Q4 		$3.08K Sell
535
-2,292
-81% -$22K ﹤0.01% 2383
2024
Q3 		$29.3K Sell
2,827
-59
-2% -$771 ﹤0.01% 1784
2024
Q2 		$37.4K Buy
2,886
+59
+2% +$796 ﹤0.01% 1743
2024
Q1 		$49.4K Hold
2,827
– – ﹤0.01% 1658
2023
Q4 		$26.6K Buy
2,827
+2,281
+418% +$21.3K ﹤0.01% 1790
2023
Q3 		$6.1K Buy
546
+36
+7% +$580 ﹤0.01% 2266
2023
Q2 		$10.9K Buy
510
+333
+188% +$9.82K ﹤0.01% 2243
2023
Q1 		$7K Sell
177
-750
-81% -$35.8K ﹤0.01% 2202
2022
Q4 		$43K Sell
927
-9
-1% -$410 ﹤0.01% 1824
2022
Q3 		$42K Sell
936
-271
-22% -$15.8K ﹤0.01% 1805
2022
Q2 		$57K Buy
1,207
+750
+164% +$40.7K ﹤0.01% 1692
2022
Q1 		$33K Sell
457
-1,077
-70% -$70.1K ﹤0.01% 1943
2021
Q4 		$91K Sell
1,534
-2,886
-65% -$226K ﹤0.01% 1546
2021
Q3 		$251 Sell
4,420
-2,014
-31% -$99.6K ﹤0.01% 1328
2021
Q2 		$283 Hold
6,434
– – ﹤0.01% 1298
2021
Q1 		$317 Hold
6,434
– – ﹤0.01% 1317
2020
Q4 		$271K Buy
6,434
+2,762
+75% +$122K ﹤0.01% 1355
2020
Q3 		$168K Buy
3,672
+3,032
+474% +$147K ﹤0.01% 1369
2020
Q2 		$32K Buy
640
+500
+357% +$25.9K ﹤0.01% 1672
2020
Q1 		$7K Buy
140
+50
+56% +$2.67K ﹤0.01% 1904
2019
Q4 		$6K Hold
90
– – ﹤0.01% 1909
2019
Q3 		$5K Hold
90
– – ﹤0.01% 1895
2019
Q2 		$8K Hold
90
– – ﹤0.01% 1807
2019
Q1 		$9K Hold
90
– – ﹤0.01% 1780
2018
Q4 		$6K Hold
90
– – ﹤0.01% 1761
2018
Q3 		$8K Buy
+90
New +$9.02K ﹤0.01% 1779

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Nisa Investment Advisors's ENTA Position: Q1 2026 in Review

Nisa Investment Advisors held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 340 shares worth $4.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2484.

Nisa Investment Advisors first reported a position in ENTA in Q3 2018 and has held it in 31 quarters since. The position peaked at $271K in Q4 2020. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Nisa Investment Advisors held 340 shares of Enanta Pharmaceuticals worth $4.29K as of Q1 2026.
  • Nisa Investment Advisors left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2484 holding.
  • Nisa Investment Advisors first reported a position in Enanta Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Nisa Investment Advisors's Enanta Pharmaceuticals position peaked at $271K in Q4 2020.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.